lenalidomide has been researched along with Bilirubinemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adam, Z; Adamová, Z; Boichuk, I; Dvořáková, K; Koukalová, R; Král, Z; Krejčí, M; Packová, B; Pour, L; Řehák, Z; Sandecká, V; Štork, M | 1 |
| Beedie, SL; Chau, CH; Figg, WD; Gere, S; Huang, PA; Kazandjian, D; Korde, N; Landgren, O; Mailankody, S; Venzon, DJ | 1 |
1 trial(s) available for lenalidomide and Bilirubinemia
| Article | Year |
|---|---|
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Gene Expression; Genotype; Humans; Hyperbilirubinemia; Hypoalbuminemia; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Polymorphism, Single Nucleotide; Prospective Studies; Treatment Outcome; Ubiquitin-Protein Ligases | 2019 |
1 other study(ies) available for lenalidomide and Bilirubinemia
| Article | Year |
|---|---|
Slow increase of bilirubin concentration during administration of lenalidomide, bortezomib and dexamethasone for multiple myeloma (unmasking previously undiagnosed Gilbert syndrome) and disappearance of necrobiotic xanthogranuloma after complete remission
Topics: Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Bortezomib; Dexamethasone; Gilbert Disease; Humans; Hyperbilirubinemia; Lenalidomide; Multiple Myeloma; Necrobiotic Xanthogranuloma; Positron Emission Tomography Computed Tomography | 2022 |